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Nationwide Voluntary Recall of All Products for Sterile Use from 
Compounding Pharmacy located in Cedar Park, Texas
Summary:
The U.S. Food and Drug Administration (FDA) is alerting health care providers and patients of a voluntary 
nationwide recall of all products produced and distributed for sterile use by Specialty Compounding, LLC, 
Cedar Park, Texas. There have been recent reports of bacterial bloodstream infections potentially related 
to the company's calcium gluconate infusions.
CDC and the FDA are working with Texas state officials to determine the scope of the contamination.
According to the FDA, information provided by the firm stated that the recalled products (i.e., all products 
produced and distributed for sterile use by Specialty Compounding) were distributed directly to patients 
nationwide, with the exception of North Carolina, which received no products. The full text of the recall is 
available on the FDA website at http://www.fda.gov/Safety/Recalls/ucm364643.htm?source=govdelivery. 
Also according to the FDA, information provided by the firm stated that recalled products were also 
distributed to hospitals and physician offices in Texas.
Background
The Texas Department of State Health Services has reported bacterial bloodstream infections in 15 
patients from two Texas hospitals who received an infusion of calcium gluconate 2 grams in Sodium 
Chloride 0.9 percent for Injection, supplied by Specialty Compounding. According to Texas state officials, 
most infections were caused by Rhodococcus equi and are thought to be related to the infusions. Two of 
the 15 patients have died. CDC does not have information that the deaths are related to recalled 
product. Also according to Texas state officials, cultures from an intact sample of calcium gluconate 
compounded by Specialty Compounding show growth of bacteria that are consistent with Rhodococcus 
species. Isolates are being evaluated by CDC to confirm the identification.
Recommendations
All sterile use products produced and distributed by Specialty Compounding are being recalled, and none 
of these products should be used by patients or administered to patients. Facilities, health care providers, 
and patients who have received the products, should immediately discontinue use, quarantine the 
products, and return the products to Specialty Compounding (See 
http://www.fda.gov/Safety/Recalls/ucm364643.htm?source=govdelivery) .
If patients who received recalled product are experiencing symptoms, especially fever, they should 
consult a physician.
Patients and physicians should report adverse reactions experienced with the use of any Specialty 
Compounding products to the FDA's MedWatch Adverse Event Reporting program either online, by 
regular mail, or by fax. Information on reporting adverse reactions can be found at:
• https://www.accessdata.fda.gov/scripts/medwatch/
• Download form at
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm or call 1-800­
332-1088 to request a reporting form, then complete and mail to the address on the pre­
addressed form, or submit by fax to 1-800-FDA-0178.
Additional Information
As more information becomes available, CDC will provide updates on the situation via the Health Alert 
Network.
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